Head-to-head · updated 2026-09-17
Ro vs Noom Med
Last verified 2026-09-20 · methodology · conflict-of-interest disclosure · dataset: open JSON
On the numbers on file, Ro has the lower entry price — $149/mo versus $179/mo, both restated to a 30.44-day month. Status matters as much as price: Ro is verified, Noom Med is verified — and on this site only first-party-verified figures can settle a category. Both tables below come from the same dataset, so the prices here cannot disagree with the index. Last verified 2026-09-20.
Ro — rows on file
| Medication | From / mo | 12-mo term | Membership | Dose policy | Status |
|---|---|---|---|---|---|
| tirzepatide | $299 | — | $149 | dose_tiered | Verified |
| semaglutide | $149 | — | $149 | dose_tiered | Verified |
Noom Med — rows on file
| Medication | From / mo | 12-mo term | Membership | Dose policy | Status |
|---|---|---|---|---|---|
| semaglutide | — | — | $0 | not_stated | Unpriced |
| tirzepatide | — | — | $0 | not_stated | Unpriced |
| semaglutide | $179 | — | $0 | not_stated | Verified |
How to decide between them
Price gap first: $30/month is $360/year — real money, but only decisive if everything else ties. Then the fields that usually break the tie: dose policy (a flat rate protects month six), membership (a $0 line item that some programs quietly make $25–$79), and cancellation terms. Where a field says “not on file,” that’s a question to ask the provider directly — and a check the verification sprint will make for you. Both providers’ full files: Ro · Noom Med.
Best for
- Ro on entry price alone, per the rows above
Not best for
- Anyone for whom “verified” status isn’t enough — wait for the sprint or verify yourself with the kit
Unverified — listed, not ranked
Rows marked Reported carry third-party provenance and dates; nothing on this page is a first-party endorsement of either program.
Update log
- 2026-08-26 — Comparison generated from the live dataset per the Pass-12 audit.